<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925778</url>
  </required_header>
  <id_info>
    <org_study_id>BLS-11-403</org_study_id>
    <nct_id>NCT04925778</nct_id>
  </id_info>
  <brief_title>Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate</brief_title>
  <acronym>PERSIST</acronym>
  <official_title>An Open-label, Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® (Monomethyl Fumarate) From Dimethyl Fumarate (PERSIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banner Life Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banner Life Sciences LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, observational study evaluating GI symptoms in&#xD;
      relapsing-remitting multiple sclerosis (RRMS) patients who switch from dimethyl fumarate&#xD;
      (DMF) to Bafiertam®.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, observational study evaluating GI symptoms in&#xD;
      relapsing-remitting multiple sclerosis (RRMS) patients who switch from dimethyl fumarate&#xD;
      (DMF) to Bafiertam® (monomethyl fumarate).&#xD;
&#xD;
      Adult patients with a diagnosis of RRMS receiving continuous treatment with DMF monotherapy&#xD;
      and who are experiencing GI symptoms will be eligible to enroll in the study.&#xD;
&#xD;
      Patients will be identified and screened by chart review and invited to report GI Symptoms&#xD;
      for one baseline week using a study app downloaded on their own smartphone/tablet. During&#xD;
      this week, patients will continue their currently prescribed and remaining DMF treatment and&#xD;
      will record their GI symptoms daily using the app.&#xD;
&#xD;
      At the end of the Baseline Period, patients will be asked to cease administration of the DMF,&#xD;
      and to commence self-treatment with Bafiertam® 95 mg capsules twice a day (total daily dose&#xD;
      of 380 mg) approximately 12 hours apart the following day for 28 days. They will be required&#xD;
      to continue to record their GI symptoms each day.&#xD;
&#xD;
      On Day 28; End-of Study [EOS]) the patient's diary will be reviewed, adverse events (AE)&#xD;
      recorded, and drug accountability performed.&#xD;
&#xD;
      Following EOS patients will be asked if they wish to continue Bafiertam® treatment. Those&#xD;
      patients who elect to continue will be contacted one month and two months after EOS to&#xD;
      ascertain if they remain on Bafiertam®.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business considerations&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">September 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the frequency and severity of GI symptoms before and after switching to Bafiertam®.</measure>
    <time_frame>28 days</time_frame>
    <description>The GI tolerability of Bafiertam® following a switch from dimethyl fumarate will be assessed by determining the frequency and severity of GI events using a modified gastrointestinal symptom scale.</description>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>monomethyl fumarate</intervention_name>
    <description>Patients will be prescribed 190 mg (two 95 mg capsules) self-administered twice/day,</description>
    <other_name>Bafiertam®, BLS-11</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a confirmed diagnosis of relapsing-remitting multiple sclerosis currently&#xD;
        treated with dimethyl fumarate (DMF), and experiencing gastrointestinal symptoms&#xD;
        attributable to DMF are eligible. Sufficient patients will be enrolled until 50 evaluable&#xD;
        patients complete the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant female aged 18years and older.&#xD;
&#xD;
          2. Diagnosis of RRMS (per McDonald 2010 Criteria) at screening [Polman 2011].&#xD;
&#xD;
          3. Currently being treated with dimethyl fumarate (DMF; Tecfidera® or generic&#xD;
             equivalent). At least 1 week and 1 day of continuous treatment with DMF monotherapy&#xD;
             prior to initiation of Bafiertam®. Note: continuous treatment with DMF is defined as&#xD;
             treatment uninterrupted by other disease-modifying treatment.&#xD;
&#xD;
          4. GI symptoms (defined as any combination of abdominal pain, nausea, vomiting, diarrhea,&#xD;
             constipation, bloating, or flatulence) while receiving treatment with DMF.&#xD;
&#xD;
          5. Must be naïve to Bafiertam®.&#xD;
&#xD;
          6. Additional inclusion criteria apply&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS&#xD;
             (as defined by Lublin and Reingold) [Lublin 2014].&#xD;
&#xD;
          2. Females breastfeeding, pregnant, or planning to become pregnant; or women who have a&#xD;
             positive pregnancy test result during screening.&#xD;
&#xD;
          3. History of severe hypersensitivity (e.g., anaphylaxis or anaphylactoid reactions) to&#xD;
             the active ingredient (monomethyl fumarate), dimethyl fumarate, diroximel fumarate&#xD;
             (Vumerity®), or any of the excipients.&#xD;
&#xD;
          4. Lymphocyte counts less than 1000/microliter. Any other clinically significant&#xD;
             abnormalities in CBC, blood and urine chemistries, or liver function tests in the past&#xD;
             30 days.&#xD;
&#xD;
          5. History of severe opportunistic infections (including progressive multifocal&#xD;
             leukoencephalopathy (PML) and herpes zoster) or any clinically significant, cardiac,&#xD;
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,&#xD;
             neurologic (other than MS), dermatologic, psychiatric, and renal, or other major&#xD;
             disease, as determined by the Investigator.&#xD;
&#xD;
          6. Any prior suspicion of PML.&#xD;
&#xD;
        9. Additional exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas W Lategan, D.Phil.</last_name>
    <role>Study Director</role>
    <affiliation>Banner Life Sciences LLC</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bafiertam</keyword>
  <keyword>Tecfidera</keyword>
  <keyword>dimethyl fumarate</keyword>
  <keyword>monomethyl fumarate</keyword>
  <keyword>gastrointestinal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

